논문 검색
-
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma.
[BACKGROUND] The potential of Lenvatinib to synergize with combined radiotherapy and immunotherapy in LUAD remains incompletely characterized. [METHODS] We investigated Lenvatinib's effects on radiation-induced PD-L1 in LUAD cells and VEGF…
FULLTEXT: complement versus -
The distinct roles of and in proximal- and late-onset colorectal cancer.
Despite the emerging role of the gut microbiome in colorectal cancer (CRC), its significance in early-onset CRC (EOCRC, …
FULLTEXT: complement versus -
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes.
[BACKGROUND AND PURPOSE] The benefit of adding anti-PD-1 antibodies to definitive chemoradiotherapy (dCRT) in elderly patients with esophageal squamous cell carcinoma (ESCC) remains uncertain. This study evaluated its efficacy and safety ve…
FULLTEXT: complement versus -
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.
[AIMS] In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-…
FULLTEXT: complement versus -
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
[AIMS] Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma (CIS) is aggressive and treatment options are suboptimal. TAR-200, a novel intravesical drug-releasing system, receiv…
FULLTEXT: complement versus -
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
[BACKGROUND AND AIM] Bruton tyrosine kinase inhibitors (BTKis) are the standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib and acalabrutinib are two commo…
FULLTEXT: complement versus -
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.
[BACKGROUND] Bruton tyrosine kinase inhibitors (BTKis) are therapeutic agents for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Previous indirect treatment comparisons are limited in simultaneously comparing multiple intervent…
FULLTEXT: complement versus -
A Randomized Trial Evaluating Intraoperative Ischemic Preconditioning of Parathyroid Glands During Total Thyroidectomy: A Signal for Earlier Parathyroid Function Recovery.
[BACKGROUND] Ischemic preconditioning of parathyroid glands (IPCP) is biologically plausible but clinical evidence is limited. In this single-center randomized trial (ChiCTR2000039788), we compared IPCP versus control during total thyroidec…
FULLTEXT: complement versus -
Impact of Adjuvant Chemotherapy on Survival of the Patients with pT1N + M0 Gastric Cancer: A Retrospective Cohort Study.
[BACKGROUND] The advantages of postoperative adjuvant chemotherapy (ACT) for gastric cancer patients with pT1N + M0 staging have been a subject of debate. This study aims to assess whether ACT can enhance the overall survival (OS) of postop…
FULLTEXT: complement versus -
Causal Caution Before Declaring Superiority of Liver Resection Versus Radiofrequency Ablation for Very Early-Stage Hepatocellular Carcinoma.
FULLTEXT: complement versus
-
Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.
[BACKGROUND] Several colorectal cancer (CRC) screening modalities are guideline-recommended in the United States but differ in screening interval and real-world adherence. Accordingly, single-round test performance may not reflect cumulativ…
FULLTEXT: complement versus -
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
[AIM] To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs). [METHODS] A survey of 105 clinical experts acro…
FULLTEXT: complement versus -
A Retrospective Comparative Study on the Omission Versus Placement of Chest Drain Following Thoracoscopic Sublobar Resection.
[PURPOSE] This study aims to investigate the clinical applicability of omitting chest drainage tube following thoracoscopic sublobar resection. [METHODS] We gathered data from 1,054 patients who met the inclusion criteria and underwent tho…
FULLTEXT: complement versus -
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.
[AIM] Recent clinical guidelines recommend pembrolizumab plus chemotherapy and cemiplimab plus chemotherapy as key first-line treatment options for metastatic non-small cell lung cancer (mNSCLC). We evaluated the cost-effectiveness of these…
FULLTEXT: complement versus -
Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis.
[OBJECTIVE] To investigate the efficacy and adverse reactions of radiotherapy with omitted clinical target volume (CTV) in unresectable stage III non-small cell lung cancer (NSCLC). [METHODS] A total of 423 NSCLC patients admitted to our h…
FULLTEXT: complement versus -
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
[BACKGROUND] This study evaluated the cost-effectiveness of Tepotinib versus Capmatinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 Skipping Mutations in China. [METHODS] An economic evaluati…
FULLTEXT: complement versus -
Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
[OBJECTIVES] Real-world evidence (RWE) is increasingly used in health technology assessment (HTA) to address uncertainties surrounding the generalizability of randomized clinical trial (RCT) data. Pembrolizumab plus platinum-based chemother…
FULLTEXT: complement versus -
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
[OBJECTIVES] Novel first-line (1L) combination regimens offer improved efficacy for patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced or metastatic non-small cell lung cancer (NSCLC) versus the standard of care…
FULLTEXT: complement versus -
Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary.
[AIM] Anti-PD-(L)1 agents, inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1), are established therapies that improve cancer management as well as the disease and societal burden of specific metastatic and early-stag…
FULLTEXT: complement versus -
Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.
[AIMS] The rapid development of therapies linked to molecular biomarkers has increased the importance of next-generation sequencing (NGS)-based tumor profiling to guide treatment decisions. Technology has enabled more comprehensive clinical…
FULLTEXT: complement versus